When was SpeeDx founded?

SpeeDx was founded in 2009 and raised its 1st funding round 7 years after it was founded.

Where is SpeeDx located?

SpeeDx is headquartered in Sydney, Australia.

How many employees does SpeeDx have?

As of May 31, 2026, the latest employee count at SpeeDx is 86.

Is SpeeDx a funded company?

SpeeDx is a funded company, having raised a total of $78M across 8 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Dec 22, 2016.

When was the latest funding round of SpeeDx?

SpeeDx's latest funding was a $***** Series C round on Feb 28, 2023, with participation from 4 investors.

Where does SpeeDx rank among its competitors?

SpeeDx ranks 33rd amongst 428 active competitors, of which 93 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Daye, which secured $576K in Nov, 2025.

Who are the top competitors of SpeeDx?

SpeeDx's top competitors include Adaptive Biotechnologies, MeMed and HaystackAnalytics. Among them, Daye secured the most recent funding round in November, 2025.

SpeeDx - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provider of qPCR-based molecular diagnostics platform. The company's products include multiplexed assays for HSV-1 and -2, VZV, and Syphilis, and detecting the presence of Mycoplasma genitalium as well as antibiotic resistance. The products are based on plexZyme technology where primers amplify target nucleic acid sequences and produce an amplicon.

Website: plexpcr.com/home-us/
Social
Phone Number: +61 **********

Key Metrics

Founded Year

2009

Location

Sydney, Australia

Stage

Series C

Total Funding

$78M in 8 rounds

Latest Funding Round

Series C, Feb 28, 2023, $*****

Investors

Northpond Ventures & 10 more

Ranked

33^rd among 428 active competitors

Employee Count

86 as on May 31, 2026

Similar Companies

Adaptive Biotechnologies & 444 more

View SpeeDx's full profile

SpeeDx has raised a total funding of $78M over 8 rounds. Its first funding round was on Dec 22, 2016. Its latest funding round was a Series C round on Feb 28, 2023 for $*****. 4 investors participated in its latest round. SpeeDx has 11 institutional investors.

Here is the list of recent funding rounds of SpeeDx:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 28, 2023	8751788	Series C	2411273	9732397	3626262	1793629
May 10, 2021	4617031	Grant (prize money)	3066450	6376276	6271025	CARB-X
Sep 03, 2020	5172581	Grant (prize money)	2907610	3184844	7177889	MTPConnect

Access funding benchmarks and valuations. Sign up today!

View details of SpeeDx's funding rounds and investors

The founders of SpeeDx is Alison V Todd. Jeremy Stackawitz is the CEO of SpeeDx.

Here are the details of SpeeDx's key team members:

Alison V Todd: Co-Founder of SpeeDx.
Jeremy Stackawitz: CEO of SpeeDx.

View details of SpeeDx's Founder profiles and Board Members

SpeeDx's employee count trend

SpeeDx has 86 employees as of May 26. Here is SpeeDx's employee count trend over the years:

Uncover SpeeDx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of SpeeDx include Adaptive Biotechnologies, MeMed and HaystackAnalytics. Here is the list of Top 10 competitors of SpeeDx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Adaptive Biotechnologies 2009, Seattle (United States), Public	Provider of clinical diagnostics, and drug discovery for immune diseases	$419M	Viking Global Investors, Matrix & 21 others	72/100
2nd	MeMed 2009, Tirat Carmel (Israel), Series D	Provider of machine learning based diagnostic solutions for infectious diseases	$163M	La Maison Partners, Ping An & 23 others	69/100
3rd	HaystackAnalytics 2018, Mumbai (India), Seed	Provider of genomics technology for personalized clinical decisions	$17.3M	STRIVE, Sun Pharma & 33 others	67/100
4th	Inflammatix 2016, San Francisco (United States), Series E	Provider of diagnostic solutions for systemic infections	$191M	Khosla Ventures, Think.Health & 16 others	64/100
5th	Huwel Life 2015, Hyderabad (India), Series A	Molecular diagnostic solutions and products for the healthcare industry	$5.74M	Bartronics, BIRAC & 3 others	59/100
6th	Karius 2014, Redwood City (United States), Series C	Provider of diagnostics for identifying infectious diseases using microbial DNA	$315M	Khosla Ventures, Gilde Healthcare & 16 others	58/100
7th	Mylab 2016, Pune (India), Seed	Developer of diagnostic kits for pathogen detection and viral load monitoring	-	Rising Sun Holdings, Zydus Life & 10 others	57/100
8th	Seegene Technologies 2000, Seoul (South Korea), Public	Provider of advanced molecular diagnostics solutions	-	IMM Investment, Songhyun Investment & 3 others	56/100
9th	Daye 2018, London (United Kingdom), Series A	Manufacturer of period care products and provider of health tests	$19.2M	Salica Investments, Kindred Capital & 25 others	56/100
10th	Clear Labs 2014, Menlo Park (United States), Series D	Provider of food safety technologies for the identification of pathogens	$171M	Menlo Ventures, Redmile Group & 26 others	56/100
33rd	SpeeDx 2009, Sydney (Australia), Series C	Provider of qPCR-based molecular diagnostics platform	$78M	Northpond Ventures, Illumina Ventures & 9 others	46/100